NBP — NovaBridge Biosciences Share News
0.000.00%
Last trade - 00:00- $158.92m
- -$31.93m
Brief: I-Mab Announces Open Market Purchases Of Company American Depositary Shares By Board Member
Brief: I-MAB Announces Portfolio Prioritization Of Givastomig As Lead Clinical Program
I-Mab expected to post a loss of 22 cents a share - Earnings Preview
Brief: I-Mab Randomized Phase 2 Study Of Uliledlimab In Combination With Pembrolizumab Plus Chemotherapy Expected To Begin In 1H 2025
I-Mab expected to post a loss of 22 cents a share - Earnings Preview
I-Mab expected to post a loss of 22 cents a share - Earnings Preview
Brief: I-Mab Announces Leadership Transitions
Brief: I-Mab, Bristol Myers Squibb Collaborate To Evaluate Givastomig In A Combination Study For Newly Diagnosed Gastric, Esophageal Cancers
Brief: I-Mab Announces Encouraging Phase 1 Clinical Data Of PD-L1x4-1BB Bispecific Antibody Ragistomig At Asco 2024
U.S. STOCKS ON THE MOVE-Nvidia, KKR Real Estate Finance Trust, Amgen
U.S. STOCKS ON THE MOVE-Tiptree, Chipotle, Cincinnati Financial
U.S. STOCKS ON THE MOVE-Roblox, Fortinet, Triumph Group
Biotech firm I-Mab rises on plan to divest China operations
Biotech firm I-Mab to divest China operations (updated)
Brief: I-Mab Signs Agreement To Divest Its Assets And Business Operations In China
Biotech firm I-Mab to divest China operations
Brief: T Investment Limited Reports 9.89% Stake In I-Mab As Of November 22- SEC Filing
Brief: Felzartamab Granted Breakthrough Therapy Designation by U.S. FDA for Primary Membranous Nephropathy
Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503